Efficiency, Safety and Portability of Neovasculgen

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 1, 2011

Study Completion Date

July 1, 2011

Conditions
Peripheral Arterial Disease
Interventions
DRUG

Neovasculgen (Cambiogeneplasmid)

treatment

Trial Locations (3)

119991

Russian National Surgery Center by Petrovsky, Moscow

150000

Yaroslavl State Medical Academy, Yaroslavl

390026

Ryazansky State Medical University, Ryazan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Artgen Biotech

OTHER

NCT03068585 - Efficiency, Safety and Portability of Neovasculgen | Biotech Hunter | Biotech Hunter